openPR Logo
Press release

Active principle for cancer medication MGN1703 proven

10-25-2010 08:22 AM CET | Health & Medicine

Press release from: MOLOGEN

/ PR Agency: MOLOGEN AG - Department for Corporate Communiations
specialists in the research and development of innovative medications on the basis of DNA structures.

specialists in the research and development of innovative medications on the basis of DNA structures.

MOLOGEN AG has taken a significant step forward in the development of its cancer medication. A further evaluation sequence of data from the company’s clinical study shows by means of biomarkers the potential of the active ingredient in the therapy of cancer.

MOLOGEN AG has evaluated a further sequence of clinical data from the completed phase Ib trial with the cancer medication MGN1703. The analysis of biomarkers of the patients’ immune system exemplarily shows the effect of MGN1703 on the immune system of cancer patients. It was shown that the immune system of the patients is broadly activated and in a manner that is necessary for a successful battle with tumor diseases.

The exemplary data achieved from the clinical trial confirms the results shown in preclinical trials and in vitro studies.

Prof. Dr. Burghardt Wittig, Chairman of the scientific advisory board of MOLOGEN AG, has commented: ”The evidence of activation markers for all cellular check points of the immune system can now be shown for the first time in patients with heavily damaged immune systems. The scientific concept of dSLIM®, the molecule which is behind MGN1703, has been confirmed by this once again.”

The data was seen as very positive, in light of the health condition of the patients who were being treated in the already completed clinical study of phase Ib. The immune system of the patients had been severely damaged from several month-long pretreatments with various types of chemotherapy, and as such, a successful evaluation of the biomarkers can not be assumed per se.

Dr. Matthias Schroff, CEO of MOLOGEN AG, has responded very optimistically to these interim results: "We have additional data on hand which proves the comprehensive effect of MGN1703 on the immune system. My confidence - especially as a scientist - is greater than ever that our current Phase II/III study will show the efficacy of the medication. We have been able to establish a link in the chain of evidence with this which should be meaningful not only for our entire product pipeline, but also for investors."

The cancer medication MGN1703 is currently being investigated in the course of a phase II/III clinical study that is relevant for the approval in the treatment of metastasized colorectal cancer. The goal of the study is to significantly prevent the progression of the cancer significantly longer than has been possible with the treatment methods up to now. The study is currently being conducted at various study centers in Germany and Austria. First results shall be available after an interim evaluation in the first half of 2011

More: www.mologen.com/data/News/EN_Mitteilungen/2010/100930.shtml

The MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase.

The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange. (ISIN DE0006637200).

Memberships in associations:
BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE®, dSLIM ® and MOLOGEN ® are registered trademarks of MOLOGEN AG.

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

MOLOGEN AG
Department for Corporate Communiations
Fabeckstr. 30
D-14195 Berlin

Contact:
Prof. Peter W. Hübner
Head of Corporate Communications

T. +49 - 30 - 84 17 88 - 38
F. +49 - 30 - 84 17 88 - 50
www.mologen.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Active principle for cancer medication MGN1703 proven here

News-ID: 148975 • Views: 870

More Releases for DNA

Recombinant DNA Technology Market -
Recombinant DNA technology has allowed the transfer of desired characteristics which is useful to improve the existing systems by controlling expression of target genes. Recombinant DNA technology allows mass production of therapeutic proteins, which are characterized by high level of consistency and stability. The technology has multidisciplinary applications and potential to deal with important aspects of life, for instance, improving health, and enhancing food resources. The genetically modified plants have
Synbio Technologies Revolutionizes DNA Synthesis
DNA Synthesis Definition and Methods DNA synthesis definition DNA synthesis is defined as the process by which copies of nucleic acids are strung together to form a longer DNA sequence within a laboratory setting. DNA synthesis processes DNA oligomers are the foundation of the DNA synthesis process. The essential feature of DNA synthesis is that no naturally isolated DNA is used. This step deviates from the traditional method of studying genetics, by which a
Global DNA Vaccine Pipeline Analysis
he global market for DNA vaccines is currently recording significant growth rates owing to the lesser side effects, ease of development, lesser cost and continued development in biotechnology arena. At present, not even a single DNA vaccine has been approved for human beings. However, around 100 products are under clinical trial for treating diseases like HIV infection, cancer and other infectious diseases. With regards to animal health, there are three
Global DNA Sequencing Market Report
MarketResearchReports.Biz announces addition of new report “Global DNA Sequencing Market Report: 2015 Edition” to its database. Description DNA sequencing market is one of the fastest growing segments of the life sciences tools market. This research study includes the market assessment of various products, technologies, applications and end-users. The report briefs about the classification in genomics, process of transcription and translation of DNA, historical development, and generations of sequencing technologies. The sequencing industry is
Global DNA Sequencing Market Report
MarketResearchReports.Biz announces addition of new report “Global DNA Sequencing Market Report: 2015 Edition” to its database. Description DNA sequencing market is one of the fastest growing segments of the life sciences tools market. This research study includes the market assessment of various products, technologies, applications and end-users. The report briefs about the classification in genomics, process of transcription and translation of DNA, historical development, and generations of sequencing technologies. The sequencing industry is
DNA Chip and DNA microarray industry NextGen Frontier for DNA Technologies – I …
A report from Transparency Market Research, titled ‘DNA Chip Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023,’ states that the global DNA chip market is expected to expand at a rapid pace during the period from 2015 to 2023 due to the increasing prevalence of cancer, the growth in personalized medicines, and technological advancements. A DNA chip, also known as a DNA microarray,